Read by QxMD icon Read

Iron iv ferritin

Martijn F Hoes, Niels Grote Beverborg, J David Kijlstra, Jeroen Kuipers, Dorine W Swinkels, Ben N G Giepmans, Richard J Rodenburg, Dirk J van Veldhuisen, Rudolf A de Boer, Peter van der Meer
AIMS: Iron deficiency is common in patients with heart failure and associated with a poor cardiac function and higher mortality. How iron deficiency impairs cardiac function on a cellular level in the human setting is unknown. This study aims to determine the direct effects of iron deficiency and iron repletion on human cardiomyocytes. METHODS AND RESULTS: Human embryonic stem cell-derived cardiomyocytes were depleted of iron by incubation with the iron chelator deferoxamine (DFO)...
February 27, 2018: European Journal of Heart Failure
Mikael Kangaspunta, Johanna Haapamäki, Martti Färkkilä, Perttu Arkkila
OBJECTIVES: The main objective of our study was to determinate the effectiveness of intravenous iron treatment with ferric carboxymaltose in inflammatory bowel disease (IBD) patients. Our other objectives were to study parameters that would predict a good response to the treatment and to chart out possible side-effects of the treatment. MATERIALS AND METHODS: In our retrospective chart review study we collected clinical data and laboratory results related to IBD from medical records of 87 IBD patients who were treated with ferric carboxymaltose in Helsinki University Hospital between 2014 and 2016...
February 22, 2018: Scandinavian Journal of Gastroenterology
K K Zahidova
PURPOSE: to study efficacy of various schemes of therapy of patients with chronic heart failure (CHF) and anemia. MATERIALS AND METHODS: We included in this study 208 patients with CHF of ishemic etiology (mean age 60.6±1.4 years, 174 with and 34 without anemia). According to therapeutic regimen of the use of methoxy polyethylene glycol-epoetin beta (MEB, 0.60 mсg/kg) and intravenous (IV) iron hydroxide sucrose complex all patients were divided into 4 groups. In all patients before and after treatment we determined Hb, Ht, plasma levels of ferritin, erythropoietin (EPO), NT-proBNP, IL-1, IL-6, TNF-α, transferrin saturation (TS), total vascular peripheral resistance, and parameters of systolic and diastolic function of left ventricular (LV) myocardium (by echocardiography and doppler echocardiography)...
January 2018: Kardiologiia
Francesc Casellas Jordá, Isabel Vera Mendoza, Manuel Barreiro-de Acosta, Juan María Vázquez Morón, Javier López Román, Javier Júdez Gutiérrez
INTRODUCTION: iron deficiency anemia is a common and very relevant manifestation of inflammatory bowel disease (IBD). Although clinical practice guidelines have been published and updated on this subject, the management in the daily practice of this complication is far from optimal. OBJECTIVE: to determine the actual management, needs and limitations of anemia in IBD by means of a survey of gastroenterology specialists. MATERIAL AND METHODS: a self-administered telematic survey was carried out between April and May 2017 and was sent to SEPD members...
February 21, 2018: Revista Española de Enfermedades Digestivas
Richard P Allen, Daniel L Picchietti, Michael Auerbach, Yong Won Cho, James R Connor, Christopher J Earley, Diego Garcia-Borreguero, Suresh Kotagal, Mauro Manconi, William Ondo, Jan Ulfberg, John W Winkelman
BACKGROUND: Brain iron deficiency has been implicated in the pathophysiology of RLS, and current RLS treatment guidelines recommend iron treatment when peripheral iron levels are low. In order to assess the evidence on the oral and intravenous (IV) iron treatment of RLS and periodic limb movement disorder (PLMD) in adults and children, the International Restless Legs Syndrome Study Group (IRLSSG) formed a task force to review these studies and provide evidence-based and consensus guidelines for the iron treatment of RLS in adults, and RLS and PLMD in children...
January 2018: Sleep Medicine
Mikkel Gybel-Brask, Jens Seeberg, Lars L Thomsen, Pär I Johansson
BACKGROUND: This trial evaluated the efficacy and safety of intravenous (IV) iron isomaltoside (Monofer) in comparison with placebo in first-time female blood donors. STUDY DESIGN AND METHODS: The trial was a prospective, double blind, placebo-controlled, randomized, comparative, single-center trial of 85 first-time female blood donors. The subjects were randomly assigned 1:1 to either 1000 mg IV iron isomaltoside infusion or placebo. The primary endpoint of the trial was change in hemoglobin (Hb) from baseline to right before the third blood donation...
February 9, 2018: Transfusion
Austin G Stack, Ahmed Alghali, Xia Li, John P Ferguson, Liam F Casserly, Cornelius J Cronin, Donal N Reddan, Wael Hussein, Mohamed E Elsayed
Background: Although anaemia is a common complication of advanced chronic kidney disease (CKD), knowledge of quality of care and management practices in specialist clinics varies. We examined anaemia practices at specialist nephrology clinics within the Irish health system and evaluated the opinions of practicing nephrologists. Methods: A multicentre cross-sectional study was conducted at specialist nephrology clinics across six geographic regions in Ireland. Clinical characteristics and treatment practices were evaluated in a sample of 530 patients with CKD...
February 2018: Clinical Kidney Journal
Dhruvan Patel, Chinmay Trivedi, Nabeel Khan
PURPOSE OF REVIEW: Anemia is the most common complication as well as an extra intestinal manifestation of inflammatory bowel disease (IBD). It is associated with a significant impact on patient's quality of life (QoL); as well it represents a common cause of frequent hospitalization, delay of hospital inpatient discharge and overall increased healthcare burden. In spite of all these, anemia is still often underdiagnosed and undertreated. Our aim in this review is to provide a pathway for physicians to help them achieve early diagnosis as well as timely and appropriate treatment of anemia which in turn would hopefully reduce the prevalence and subsequent complications of this condition among IBD patients...
March 2018: Current Treatment Options in Gastroenterology
Fady M El-Gendy, Mahmoud A El-Hawy, Mohamed S Rizk, Sally M El-Hefnawy, Mohamed Z Mahmoud
There are many causes of anemia; the most common of these are acute and chronic infections, iron deficiency, or both. Identifying the cause is a very important step in management of anemia. So, we evaluated the usefulness of soluble transferrin receptor (sTfR) and of the sTfR/log ferritin in the diagnosis of iron deficiency anemia accompanied by acute infection. This study was conducted on 131 children aged 2-11 years old from those who attended the pediatric outpatient clinics in Menoufia university hospital...
January 2018: Indian Journal of Hematology & Blood Transfusion
Vivek N Iyer, Dinesh R Apala, Bibek S Pannu, Aditya Kotecha, Waleed Brinjikji, Michael D Leise, Patrick S Kamath, Sanjay Misra, Kebede H Begna, Rodrigo Cartin-Ceba, Hilary M DuBrock, Michael J Krowka, Erin K O'Brien, Rajiv K Pruthi, Darrell R Schroeder, Karen L Swanson
OBJECTIVE: To present a multiyear clinical experience with intravenous bevacizumab for the management of severe gastrointestinal bleeding and/or epistaxis in patients with hereditary hemorrhagic telangiectasia (HHT). PATIENTS AND METHODS: All patients treated with intravenous bevacizumab for severe hereditary hemorrhagic telangiectasia-related bleeding from June 1, 2013, through January 31, 2017, were included in this report. Severity of epistaxis (determined using the Epistaxis Severity Score questionnaire); hemoglobin, iron, and ferritin levels; and quality of life data were collected serially in all patients...
January 9, 2018: Mayo Clinic Proceedings
Katsuya Ikuta, Asami Shimura, Masaru Terauchi, Kazuyoshi Yoshii, Yoshihiro Kawabata
Iron-deficiency anemia (IDA) is the most common form of anemia. Iron replacement therapy is an effective treatment, but oral and previously available intravenous (IV) formulations in Japan have disadvantages such as side effects, immunogenic reactions, low dose per tablet/vial, and the need for continuous administration. Ferric carboxymaltose (FCM), which overcomes these limitations, is widely used as an IV iron preparation outside of Japan. In this single-center, open-label, single-dose escalation study, we investigated the pharmacokinetics (PK), pharmacodynamics (PD), safety, and tolerability of FCM in Japanese subjects...
January 22, 2018: International Journal of Hematology
Vineet Mishra, Priyankar Roy, Khushali Gandhi, Sumesh Choudhary, Rohina Aggarwal, Shaheen Sokabaj
BACKGROUND: Iron deficiency is the commonest treatable cause of postpartum anaemia. Parenteral iron therapy results in faster and higher replenishment of iron stores and correction of haemoglobin levels with better compliance. Ferric Carboxy Maltose is an effective and a safe option which can be administered intravenously in single total correction dose without any serious adverse effects.The study was done to evaluate the efficacy and safety of Ferric Carboxy Maltose in the treatment of iron deficiency anaemia in post-natal patients...
January 1, 2018: Journal of Nepal Health Research Council
Tee Joo Yeo, Poh Shuan Daniel Yeo, Farid Abdul Hadi, Timothy Cushway, Kim Yee Lee, Fang Fang Yin, Anne Ching, Ruili Li, Seet Yoong Loh, Shir Lynn Lim, Raymond Ching-Chiew Wong, Bee Choo Tai, Arthur Mark Richards, Carolyn S P Lam
AIMS: Iron deficiency is highly prevalent in Southeast Asians with heart failure (HF) and associated with worse outcomes. This trial aimed to assess the effect of intravenous iron in Southeast Asians hospitalized with decompensated HF. METHODS AND RESULTS: Fifty patients hospitalized for acute decompensated HF, regardless of ejection fraction, with iron deficiency (defined as serum ferritin <300 ng/mL if transferrin saturation is <20%) were randomized to receive either one dose of intravenous ferric carboxymaltose (FCM) 1000 mg or placebo (0...
January 18, 2018: ESC Heart Failure
Amreen Naqash, Rifat Ara, Ghulam N Bader
BACKGROUND: Iron deficiency anemia (IDA) is a significant problem worldwide particularly in women. The aim of the study was to evaluate the effectiveness and safety of intravenous ferric carboxymaltose (FCM) in comparison to iron sucrose (IS) in women with IDA. METHOD: Two hundred patients at Department of Obstetrics and Gynaecology, Sher-i-Kashmir Institute of Medical Sciences Medical College and Hospital, Jammu & Kashmir, India identified with IDA were enrolled for the study...
January 5, 2018: BMC Women's Health
Tamara Fernández, Alberto Martínez-Serrano, Lorena Cussó, Manuel Desco, Milagros Ramos-Gómez
Early diagnosis in Alzheimer's disease (AD), prior to the appearance of marked clinical symptoms, is critical to prevent irreversible neuronal damage and neural malfunction that lead to dementia and death. Therefore, there is an urgent need to generate new contrast agents which reveal by a noninvasive method the presence of some of the pathological signs of AD. In the present study, we demonstrate for the first time a new nanoconjugate composed of magnetic nanoparticles bound to an antiferritin antibody, which has been developed based on the existence of iron deposits and high levels of the ferritin protein present in areas with a high accumulation of amyloid plaques (particularly the subiculum in the hippocampal area) in the brain of a transgenic mouse model with five familial AD mutations...
January 18, 2018: ACS Chemical Neuroscience
Seng Chua, Sarika Gupta, Jennifer Curnow, Beata Gidaszewski, Marjan Khajehei, Hayley Diplock
BACKGROUND: Acute post-partum anaemia can be associated with significant morbidity including a predisposition for postnatal depression. Lack of clear practice guidelines means a number of women are treated with multiple blood transfusions. Intravenous iron has the potential to limit the need for multiple blood transfusions but its role in the post-partum setting is unclear. METHODS/DESIGN: IIBAPPA is a multi-centre randomised non-inferiority trial. Women with a primary post-partum haemorrhage (PPH) >1000 mL and resultant haemoglobin (Hb) 5...
December 19, 2017: BMC Pregnancy and Childbirth
Michael Jordi Wilson, Jan Willem Dekker, Emma Bruns, Wernard Borstlap, Johannes Jeekel, Jaap Jan Zwaginga, Martin Schipperus
BACKGROUND: In the treatment of preoperative anemia, which is associated with increased postoperative morbidity, iron supplementation can replace blood transfusion and erythropoiesis-stimulating agents. The aim of this study was to assess the efficacy of preoperative intravenous (IV) iron infusion in optimizing hemoglobin (Hb) levels in anemic colorectal cancer patients. STUDY DESIGN AND METHODS: A retrospective cohort study was performed on patients who underwent surgery for colorectal cancer between 2010 and 2016 in a single teaching hospital...
December 17, 2017: Transfusion
Jorge E Toblli, Gabriel Cao, Luis Rico, Margarita Angerosa
Background: Ferric carboxymaltose (FCM) is a stable, non-dextran-based intravenous iron complex used to treat iron deficiency of various etiologies. As FCM is a nonbiological complex drug and cannot be fully characterized by physicochemical analyses, it is important to demonstrate in nonclinical models that FCM similars (FCMS) have similar biodistribution. Materials and methods: A total of 30 nonanemic rats were treated weekly with 40 mg iron/kg body weight intravenous FCM, FCMS, or isotonic saline (controls) for 4 weeks...
2017: Drug Design, Development and Therapy
Andreea Ciudin, Olga Simó-Servat, Jose Maria Balibrea, Ramon Vilallonga, Cristina Hernandez, Rafael Simó, Jordi Mesa
BACKGROUND: Chronic intravenous iron administration is often required after bariatric surgery. Oral sucrosomial iron has a particular form of absorption and may represent an alternative treatment. OBJECTIVE: To assess the effect of switching to oral sucrosomial iron in patients receiving intravenous iron supplementation after bariatric surgery. PATIENTS AND METHODS: A case-control study was conducted on 40 women of childbearing age, of whom 20 were switched to oral sucrosomial iron, while 20 patients continued on intravenous iron sucrose every three months...
January 2018: Endocrinología, Diabetes y Nutrición
Louis L Huang, Darren Lee, Stefanie M Troster, Annette B Kent, Matthew A Roberts, Iain C Macdougall, Lawrence P McMahon
Background: Intravenous (IV) iron can modulate fibroblast growth factor 23 (FGF23) concentrations and cause transient but significant hypophosphataemia. However, it is unknown what other markers might be involved, especially in different patient groups. This study aimed to determine changes in bone and haematinic biomarkers following IV ferric carboxymaltose (FCM) and to identify risk factors for hypophosphataemia in pregnant subjects and those with chronic kidney disease (CKD). Methods: Changes in bone [serum FGF23, fractional excretion of phosphate urinary fractional excretion of phosphate (FEPi), serum phosphate and serum vitamin D derivatives] and haematinic [plasma hepcidin, serum ferritin and transferrin saturation (TSAT)] biomarkers after 1 g of IV FCM were followed in iron-deficient pregnant and CKD patients and compared with controls (estimated glomerular filtration rate > 60 mL/min/1...
November 17, 2017: Nephrology, Dialysis, Transplantation
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"